Major Seizure of Counterfeit Medicines in Birmingham
On 14th October, authorities confiscated over 12,000 counterfeit pens of retatrutide and tirzepatide, alongside packaging for approximately 30,000 additional products, during a raid at an industrial facility in Birmingham. This significant operation highlights the ongoing battle against the distribution of unauthorised medications.
Tim Duffield, who heads the Intelligence unit at the MHRA’s Criminal Enforcement Unit, underscored the seriousness of the situation, stating, “We are tackling the organised criminal gangs whose illegal trade in unauthorised medicines puts people at risk of serious harm.” The seized goods, valued at around £2 million, were discovered in a squalid warehouse, raising concerns about their safety, quality, and effectiveness.
Duffield further explained that products marketed as retatrutide in the UK have not received the necessary authorisation and are being distributed unlawfully outside of legitimate clinical trials. He warned that such products could represent a significant risk to public health.
Public Health Risks and Regulatory Warnings
The MHRA urges consumers to refrain from purchasing weight-loss medications from unregulated sources. Individuals considering treatment with GLP-1 medications are advised to consult healthcare professionals and ensure they obtain prescriptions from registered pharmacies. The agency has made it clear that the safety and efficacy of these unauthorised products cannot be guaranteed, and they may contain harmful substances.
This latest raid is part of an extensive series of operations conducted by the MHRA, aimed at eliminating unauthorised GLP-1 weight-loss medicines from the market. In May 2026, law enforcement apprehended two individuals at a country estate suspected of manufacturing and distributing these illegal substances, recovering around 12,000 doses along with various packaging materials and potential pharmaceutical ingredients.
Earlier in February of the same year, authorities seized approximately 2,000 doses of unauthorised weight-loss medicines that were ready for dispatch, in addition to manufacturing equipment and commercial vehicles. Notably, in October 2025, the MHRA dismantled the UK’s first illegal production facility for weight-loss medicines, confiscating 5,000 unauthorised pens of retatrutide and tirzepatide, along with thousands of empty pens and raw chemical ingredients, which could potentially yield tens of thousands of doses.
Resources for Safe Medicine Purchases
The MHRA has launched the #FakeMeds website, which offers essential guidance for consumers on how to safely purchase medications online. Those who suspect they are experiencing side effects from medications are encouraged to consult their healthcare providers and report any concerns directly through the MHRA Yellow Card scheme.
As part of its mission, the Criminal Enforcement Unit (CEU) of the MHRA plays a crucial role in combating medicines crime. It operates with the aim of safeguarding public health, maintaining trust in regulatory practices, and ensuring adherence to the law. The CEU employs a comprehensive range of strategies, including intelligence analysis and collaboration with law enforcement both locally and internationally, to disrupt criminal activities that threaten the wellbeing of the public.
The Medicines and Healthcare products Regulatory Agency (MHRA) is tasked with the regulation of all medicines and medical devices in the UK, ensuring their safety and effectiveness. Its work is grounded in thorough and evidence-based assessments aimed at balancing the benefits and risks associated with medical products.
The MHRA operates as an executive agency under the Department of Health and Social Care, committed to upholding public health standards and regulatory integrity.
For further media inquiries, please reach out via email at newscentre@mhra.gov.uk or contact us by phone at 020 3080 7651.